---
title: "Biopol Chemicals (760945) — Share Price, Financials & Analysis"
symbol: "760945"
company: "Biopol Chemicals"
canonical: "https://tapetide.com/stocks/760945"
isin: "INE0XW001014"
nse_symbol: "BIOPOL"
sector: "Chemicals"
industry: "Specialty Chemicals"
market_cap_cr: 49.27
generated_at: "2026-09-13T19:16:03.253Z"
---

# Biopol Chemicals (760945)

Canonical page: https://tapetide.com/stocks/760945

## Company

- **NSE Symbol:** BIOPOL
- **ISIN:** INE0XW001014
- **Sector:** Chemicals
- **Industry:** Specialty Chemicals
- **Stock Type:** EQUITY
- **Listed Since:** 2026-02-13
- **F&O Eligible:** No

## Latest Price

- **Price:** ₹47.7
- **Change:** +0.6 (+1.27%)
- **Open:** ₹46
- **Day High:** ₹49
- **Day Low:** ₹44.75
- **Previous Close:** ₹47.1
- **Volume:** 63600
- **As Of:** 2026-09-11T09:59:55+00:00

## Key Fundamentals

Observed at 2026-09-11T04:33:56.339643Z.

- **Market Cap:** ₹49.27 Cr
- **Classification:** SME
- **P/E (reported):** 0
- **Book Value:** ₹46.2
- **Price to Book:** 1.02
- **Dividend Yield:** 0%
- **ROE:** 17.98%
- **ROCE:** 24.67%
- **Debt to Equity:** 0.57
- **Revenue (yearly):** ₹81.4 Cr
- **Net Income:** ₹9 Cr
- **EBITDA:** ₹13.7 Cr
- **52-Week High:** ₹133.75
- **52-Week Low:** ₹39.5
- **RSI (14):** 27.41

## Growth Rates

| Metric | QoQ | 1Y | 3Y |
| --- | --- | --- | --- |
| cash flow growth | — | -429.88% | -98.29% |
| ebitda margin growth | 0% | 27.74% | -3.28% |
| net income growth | -3.23% | 109.3% | 200% |
| revenue growth | 88.37% | 65.45% | 47.24% |
| roce | — | -45.02% | -47.52% |
| roe | — | -43.33% | 27.3% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 33 | 42 | 30 | 53 | 73 | 60 | 51 | 86 | 47 |
| Expenses | 33 | 38 | 28 | 46 | 68 | 51 | 45 | 77 | 41 |
| Operating Profit | 1 | 5 | 1 | 7 | 5 | 9 | 6 | 9 | 6 |
| OPM % | 2 | 11 | 4 | 13 | 7 | 14 | 12 | 10 | 13 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 1 | 2 | 2 | 3 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 4 | 0 | 5 | 3 | 5 | 3 | 6 | 3 |
| Tax % | 58 | 4 | 46 | 6 | 6 | 0 | 8 | 3 | 8 |
| Net Profit | 0 | 4 | 0 | 5 | 3 | 5 | 3 | 6 | 3 |
| EPS in Rs | 0.14 | 5.22 | 0.14 | 4.57 | 2.65 | 4.89 | 2.56 | 5.85 | 2.51 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 |
| --- | --- | --- |
| Sales | 25.42 | 49.13 |
| Expenses | 20.99 | 42.59 |
| Operating Profit | 4.43 | 6.54 |
| OPM % | 17.43 | 13.31 |
| Other Income | 0 | 0.02 |
| Interest | 0.39 | 0.68 |
| Depreciation | 0.08 | 0.07 |
| Profit before tax | 3.96 | 5.81 |
| Tax % | 25.25 | 25.13 |
| Net Profit | 2.96 | 4.34 |
| EPS in Rs | 3.74 | 5.49 |
| Dividend Payout % | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 |
| --- | --- | --- |
| Equity Capital | 7.91 | 7.91 |
| Reserves | 1.29 | 5.63 |
| Borrowings | 3.58 | 7.68 |
| Other Liabilities | 4.77 | 10.26 |
| Total Liabilities | 17.55 | 31.48 |
| Fixed Assets | 0.21 | 0.23 |
| CWIP | 0.06 | 0 |
| Investments | 0 | 0 |
| Other Assets | 17.28 | 31.25 |
| Total Assets | 17.55 | 31.48 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 |
| --- | --- | --- |
| Cash from Operating Activity | -6.44 | -2.34 |
| Cash from Investing Activity | -0.64 | -0.02 |
| Cash from Financing Activity | 7.14 | 3.43 |
| Net Cash Flow | 0.06 | 1.07 |

### Ratios

| Item | Mar 2024 | Mar 2025 |
| --- | --- | --- |
| Debtor Days | 145.45 | 123.77 |
| Inventory Days | 121.21 | 107.04 |
| Days Payable | 77.9 | 77.77 |
| Cash Conversion Cycle | 188.76 | 153.05 |
| Working Capital Days | 127.36 | 95.17 |
| ROCE % | — | 38.18 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- |
| Promoters | 98.1% | 65.81% | 65.81% |
| FIIs | 0% | 9.3% | 4.7% |
| DIIs | 0% | 2.92% | 0.54% |
| Government | 0% | 0% | 0% |
| Public | 0% | 7.67% | 17.41% |
| Others | 1.9% | 14.31% | 11.55% |
| No. of Shareholders | 10 | 228 | 368 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 5 / 5 / 9

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 46.33 | Buy |
| EMA (10) | 51.74 | Sell |
| SMA (20) | 67.93 | Sell |
| EMA (20) | 62.87 | Sell |
| SMA (50) | 85.87 | Sell |
| EMA (50) | 79.43 | Sell |
| SMA (100) | 96.04 | Sell |
| EMA (100) | 89.45 | Sell |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 28.26 | Buy |
| MACD (12,26,9) | -13.73 | Sell |
| Stochastic (14,3,3) | 11.88 | Buy |
| ADX (14) | 37.58 | Buy |
| Williams %R (14) | -85.95 | Buy |
| ATR (14) | 5.76 | High Volatility |
| ROC (12) | -46.22 | Sell |
| Stoch RSI (14) | 34.69 | Neutral |
| UO (7,14,28) | 56.17 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 30 March 2026 - Trading window closed from April 1, 2026 until 48 hours after audited results for period ended March 31, 2026. | [Trading Window 30 March 2026 - Trading window closed from April 1, 2026 until 48 hours after audited results for period ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_30032026174513_NSE_Letter.pdf) |
| 30 January 2026 - Confirmation that securities dematerialised in quarter ended 31-Dec-2025 were processed and certificates cancelled. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 30 January 2026 - Confirmation that securities dematerialised in quarter ended 31-Dec-2025 were processed and certificates cancelled.](https://nsearchives.nseindia.com/corporate/USAL_30012026211331_Regulation74.pdf) |
| 30 April 2026 - No deviation in SME IPO proceeds; Rs. 3,125.95 lakh raised, Rs. 3,051.81 lakh utilized by March 31, 2026. | [Statement of deviation(s) or variation(s) under Reg. 32 30 April 2026 - No deviation in SME IPO proceeds; Rs. 3,125.95 lakh raised, Rs. 3,051.81 lakh utilized by March 31, 2026.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_30042026140814_Letter.pdf) |
| 30 April 2026 - Board approved audited FY26/HY26 results; revenue ₹81.14 crore, profit ₹8.97 crore, unmodified audit opinion. | [Outcome of Board Meeting 30 April 2026 - Board approved audited FY26/HY26 results; revenue ₹81.14 crore, profit ₹8.97 crore, unmodified audit opinion.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_30042026132815_Letter.pdf) |
| 30 April 2026 - Board approved audited FY26 and H1 FY26 results; auditors issued unmodified opinion. | [Updates 30 April 2026 - Board approved audited FY26 and H1 FY26 results; auditors issued unmodified opinion.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_30042026150024_Letter_fnl.pdf) |
| 25 May 2026 - Submitted SDD compliance certificate for FY 2025-26; 12 events captured, no non-compliance reported. | [Structural Digital Database 25 May 2026 - Submitted SDD compliance certificate for FY 2025-26; 12 events captured, no non-compliance reported.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_25052026155750_NSE_Letter.pdf) |
| 22 May 2026 - Board approved shifting registered office in Ahmedabad to Vatva, effective May 22, 2026. | [Address Change 22 May 2026 - Board approved shifting registered office in Ahmedabad to Vatva, effective May 22, 2026.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_22052026173046_NSE_BM_Outcome_fnl.pdf) |
| 22 May 2026 - Board approved shifting registered office from Ahmedabad Dudheshwar to Vatva, effective May 22, 2026. | [Outcome of Board Meeting 22 May 2026 - Board approved shifting registered office from Ahmedabad Dudheshwar to Vatva, effective May 22, 2026.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_22052026173610_NSE_BM_Outcome_fnl.pdf) |
| 20 April 2026 - Biopol Chemicals says corporate governance report is not applicable for quarter ended March 31, 2026. | [Updates 20 April 2026 - Biopol Chemicals says corporate governance report is not applicable for quarter ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_20042026165704_Reg_27_Non_CGR.pdf) |
| 20 April 2026 - Biopol Chemicals confirms it is not a Large Corporate as of 31 March 2026. | [Integrated Filing- Financial 20 April 2026 - Biopol Chemicals confirms it is not a Large Corporate as of 31 March 2026.](https://nsearchives.nseindia.com/corporate/BIOPOL2025_20042026164943_NSE_Letter_Large_entity_Disclosure.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27845_USASEEDS_2024_2025_A_6589712_28082025203436.pdf) |
| from nse | [Financial Year 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_26215_USASEEDS_2023_2024_09092024105922.pdf) |
| from nse | [Financial Year 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_23774_USASEEDS_2022_2023_07092023174344_09072023180030.zip) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:16:03.253Z.